Related Experiment Videos
Clinical aspects of parathyroid hypertensive factor
R Z Lewanczuk1, C G Benishin, J Shan
1Department of Physiology, University of Alberta, Edmonton, Canada.
Journal of Cardiovascular Pharmacology
|January 1, 1994
Summary
Parathyroid hypertensive factor (PHF) is linked to hypertension in humans, particularly in salt-sensitive, low-renin conditions. Treatments like calcium and calcium-channel blockers may help manage PHF-related hypertension.
Area of Science:
- Cardiovascular Physiology
- Endocrinology
- Nephrology
Background:
- Parathyroid hypertensive factor (PHF) has been implicated in hypertension in animal models.
- Its clinical significance in human hypertension requires further investigation.
Purpose of the Study:
- To determine the clinical significance of parathyroid hypertensive factor (PHF) in human hypertension.
- To explore the relationship between PHF and hypertension, particularly in salt-sensitive, low-renin states.
Main Methods:
- Parallel physiological studies in animal models and human subjects.
- Correlation analysis of PHF activity with hypertension parameters.
- Observational studies in primary hyperparathyroid patients before and after parathyroidectomy.
Main Results:
- PHF-like activity was detected in human hypertension, correlating with salt-sensitive, low-renin states.
- Supplemental calcium and calcium-channel blockers showed potential in treating PHF-related hypertension.
- PHF presence was linked to hypertension in primary hyperparathyroid patients, with blood pressure decreasing postparathyroidectomy alongside PHF levels.
Conclusions:
- PHF may serve as a clinical marker for hypertension.
- Further research is warranted to elucidate the role of PHF in hypertension management.